Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Fedro Pharmaceutical Labs Pvt Ltd

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000238 76 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx76product presentations
G30generic molecules
DF6dosage-form groups
TA7therapeutic areas
PKR76current price records
REG61registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage93%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixFedro Pharmaceutical Labs Pvt LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/fedro-pharmaceutical-labs-pvt-ltdGenerated 10 Aug 2026Anti-infectives51 · 67%CNS & mental health8 · 11%Vitamins, minerals & nutrition6 · 8%Cardiovascular4 · 5%Pain & musculoskeletal3 · 4%Gastrointestinal & hepatology2 · 3%Hematology & thrombosis2 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioFedro Pharmaceutical Labs Pvt LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/fedro-pharmaceutical-labs-pvt-ltdGenerated 10 Aug 202676presentationsTablet27 · 36%Capsule21 · 28%Suspension21 · 28%Injection5 · 7%Drops1 · 1%Syrup1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionFedro Pharmaceutical Labs Pvt LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/fedro-pharmaceutical-labs-pvt-ltdGenerated 10 Aug 202671comparable productsBelow market median30 · 42%Near market median24 · 34%Above market median17 · 24%Company median price position-1.9%Lowest-price equivalents6Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsFedro Pharmaceutical Labs Pvt LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/fedro-pharmaceutical-labs-pvt-ltdGenerated 10 Aug 2026Zafa Pharmaceutical Laboratories (P…22 shared73% overlapMediate Pharmaceutical Pvt Ltd20 shared67% overlapBio-Labs(Pvt) Ltd20 shared67% overlapNabiqasim Industries (Pvt) Ltd.,19 shared63% overlapGlobal Pharmaceuticals Pvt Ltd19 shared63% overlapFriends Pharma (Pvt.) Ltd.19 shared63% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives51 products · 67%
CNS & mental health8 products · 11%
Vitamins, minerals & nutrition6 products · 8%
Cardiovascular4 products · 5%
Pain & musculoskeletal3 products · 4%
Gastrointestinal & hepatology2 products · 3%
Hematology & thrombosis2 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

First-generation cephalosporins12 products · 16%
Penicillin antibacterials10 products · 13%
Antipsychotics6 products · 8%
Vitamins / minerals / hematinics6 products · 8%
Nitroimidazole anti-infectives6 products · 8%
Fluoroquinolone antibacterials5 products · 7%
Macrolide antibacterials5 products · 7%
Third-generation cephalosporins4 products · 5%
Formulation footprint

Dosage forms

Tablet27 products
Capsule21 products
Suspension21 products
Injection5 products
Drops1 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 FedraxilAmoxicillin 8presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #2 CephdroCephradine 6presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #3 FedmaltIron 4presentations 100 mg, 50 mg/5 mL, 50 mg/mL · Tablet, Syrup, Drops #4 FedroximeCefixime 4presentations 100 mg/5 mL, 200 mg, 200 mg/5 mL, 400 mg · Suspension, Capsule #5 CefilxinCephalexin 3presentations 125 mg/5 mL, 250 mg/5 mL · Suspension #6 Deprefed-O 12Olanzapine 3presentations 25 mg · Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3042% of comparable products
Near market median24within ±5% of median
Above market median1724% of comparable products
Lowest-price equivalents6ties included
Company median price position -1.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Leefed 250 mgLevofloxacin · Tablet · 10s PKR 23.54/tablet-50.5% vs market median Leefed 500 mgLevofloxacin · Tablet · 10s PKR 40.41/tablet-48.6% vs market median Fedzobac 2 g + 0.25 gPiperacillin + tazobactam · Injection · 1s PKR 368.01/vial/unit-48.3% vs market median Di-Mether 20 mg + 120 mgArtemether + Lumefantrine · Tablet · 16s PKR 20.73/tablet-46.6% vs market median Fedzobac 4 g + 0.5 gPiperacillin + tazobactam · Injection · 1s PKR 836.68/vial/unit-45.2% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Zafa Pharmaceutical Laboratories (Pvt) Ltd.239 products · 98 generics 22shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 20shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 20shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 19shared generics Global Pharmaceuticals Pvt Ltd211 products · 80 generics 19shared generics Friends Pharma (Pvt.) Ltd.90 products · 47 generics 19shared generics
Regulatory & price activity

Observed database signals

Registration numbers61
Price-history records89
Products with price history12
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date30 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

76 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Fedroxime Cefixime 100 mg/5 mL Dry suspension 30ml 075505 PKR 330.40 PKR 11.01/mL 5% above median
Fedroxime Cefixime 200 mg/5 mL Dry suspension 30ml 075506 PKR 404.34 PKR 13.48/mL Near median
Fedroxime Cefixime 400 mg Capsule 5s 075504 PKR 592.05 PKR 118.41/capsule Near median
Fedroxime Cefixime 200 mg Capsule 5s 075503 PKR 319.90 PKR 63.98/capsule Near median
Fedxamic Tranexamic acid 250 mg Capsule 100s 101037 PKR 1,097.40 PKR 10.97/capsule Near median
Fedxamic Tranexamic acid 500 mg Capsule 20s 101038 PKR 422.08 PKR 21.10/capsule Near median
Fedzobac Piperacillin + tazobactam 4 g + 0.5 g Injection 1s 120049 PKR 836.68 PKR 836.68/vial/unit 45% below median
Fedzobac Piperacillin + tazobactam 2 g + 0.25 g Injection 1s 120050 PKR 368.01 PKR 368.01/vial/unit 48% below median
Femazole Clotrimazole 500 mg Tablet 1s 034271 PKR 127.67 PKR 127.67/tablet 5% above median
Fluco-Z Fluconazole 150 mg Capsule 1s 038174 PKR 343.10 PKR 343.10/capsule 31% above median
Leefed Levofloxacin 250 mg Tablet 10s 059492 PKR 235.39 PKR 23.54/tablet 50% below median
Leefed Levofloxacin 500 mg Tablet 10s 051147 PKR 404.07 PKR 40.41/tablet 49% below median
Vanpin Simvastatin 20 mg Tablet 10s 034274 PKR 393.65 PKR 39.37/tablet 13% below median
Zefed Azithromycin 250 mg Tablet 6s 059494 PKR 299.21 PKR 49.87/tablet 6% above median
Zefed Azithromycin 500 mg Tablet 6s 059495 PKR 548.56 PKR 91.43/tablet 8% above median
Zefed Azithromycin 200 mg/5 mL Dry suspension 15ml 108725 PKR 233.10 PKR 15.54/mL 26% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.